Discovery of Potent Hepatitis C Virus NS5A Inhibitors with Dimeric Structures
Julie A. Lemm(Bristol-Myers Squibb (United States)), Min Gao(Central South University), Xiaohua Huang(City Of Hope National Medical Center), Joseph L. Cantone(Bristol-Myers Squibb (United States)), Nicholas A. Meanwell(Mario Negri Institute for Pharmacological Research), Donald R. O’Boyle(Bristol-Myers Squibb (United States)), John E. Leet(Franklin University), Daniel R. Schroeder(Bristol-Myers Squibb (United States)), Peter T. Nower, Jin-Hua Sun(University of Science and Technology of China), J. Romine(Bristol-Myers Squibb (United States)), Michael H. Serrano‐Wu(Broad Institute), Jeffrey R. Alberts(Indiana University Bloomington), Lawrence B. Snyder(Arvinas (United States)), Scott Martin(Bristol-Myers Squibb (United States))
Cited by 57
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
Highly Active and Selective Catalysts for the Formation of α-Aryl Ketones
|Journal of the American Chemical Society|2000|517
Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
|Nature Immunology|2021|422
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
|Nature Biotechnology|2024|258
Applications of fluorine-containing amino acids for drug design
|European Journal of Medicinal Chemistry|2019|238